Glaucoma Treatment Options: Eye Drops, Laser, and Surgery Compared

The "Silent Thief of Sight" Affects 80 Million Worldwide

Glaucoma is the leading cause of irreversible blindness globally, affecting an estimated 80 million people — with approximately half undiagnosed. The hallmark is progressive optic neuropathy: pressure-mediated or vascular damage to the retinal ganglion cell axons that form the optic nerve, resulting in characteristic visual field loss that begins in the periphery and advances toward central vision. By the time most patients notice symptoms in primary open-angle glaucoma (POAG), the most common form, they have already lost 30–40% of their optic nerve fibers. Damage is permanent and irreversible — which is why treatment focuses on halting progression rather than restoring lost vision.

Every treatment option for glaucoma shares one unifying goal: lower intraocular pressure (IOP).

Understanding Glaucoma Types and IOP Targets

Intraocular pressure, normally between 10–21 mmHg, is the only modifiable risk factor proven to slow glaucoma progression. Even "normal-tension glaucoma" — in which optic nerve damage occurs despite statistically normal IOP — responds to IOP reduction. Treatment targets are individualized based on the degree of optic nerve damage, the baseline IOP, and the presence of risk factors such as thin central corneal thickness, family history, or the presence of pseudoexfoliation syndrome.

First-Line Treatment: Topical Eye Drops

Medicated eye drops remain the most common first-line treatment for glaucoma, reducing IOP either by decreasing aqueous humor production or increasing its outflow. Adherence is the Achilles heel of topical therapy: studies consistently show that patients use drops correctly and consistently only 50–70% of the time, a crucial issue given that most glaucoma drops must be instilled once or twice daily for life.

• Prostaglandin analogs (latanoprost, bimatoprost, travoprost, tafluprost): First-line for most patients; once-daily evening dosing; reduce IOP by 25–35% by increasing uveoscleral outflow; side effects include iris and periorbital pigmentation changes, eyelash growth, and periorbital fat atrophy with long-term use
• Beta-blockers (timolol, betaxolol): Reduce aqueous production; once or twice daily; effective at 20–25% IOP reduction; contraindicated in asthma, significant COPD, bradycardia, and decompensated heart failure; betaxolol is beta-1 selective and carries lower respiratory risk
• Carbonic anhydrase inhibitors — topical (dorzolamide, brinzolamide): Reduce aqueous production; 15–20% IOP reduction; used as adjuncts; oral acetazolamide/methazolamide offer greater efficacy but systemic side effects (metabolic acidosis, kidney stones, sulfa allergy risk) limit long-term use
• Alpha-2 agonists (brimonidine): Dual mechanism — reduce aqueous production and increase uveoscleral outflow; 20–25% IOP reduction; twice or three times daily; cross blood-brain barrier and cause somnolence, particularly dangerous in infants and toddlers; allergic conjunctivitis in 10–15% long-term
• Rho kinase inhibitors (netarsudil): Increase conventional trabecular outflow; reduces IOP 15–20%; may benefit normal-tension glaucoma specifically; causes conjunctival hyperemia in majority of users

Fixed-combination drops (e.g., latanoprost/timolol, brimonidine/timolol) improve adherence by reducing the number of individual bottles.

Laser Trabeculoplasty: Safe, Effective, and Underused

Selective laser trabeculoplasty (SLT) applies 532-nm frequency-doubled Nd:YAG laser energy to the trabecular meshwork, selectively targeting pigmented cells and triggering macrophage-mediated remodeling that enhances aqueous outflow. Unlike argon laser trabeculoplasty (ALT), SLT causes no thermal coagulation of trabecular tissue and can be repeated. The landmark LiGHT trial (2019, Lancet) found that SLT as initial therapy was non-inferior to eye drops at controlling IOP at 3 years, with 74% of SLT-treated patients requiring no additional medication at 3 years, compared to 93% adherence with drops — a meaningfully important finding given real-world adherence challenges.

Surgical Options: MIGS to Trabeculectomy

Surgery is typically reserved for patients who fail to achieve target IOP on maximum tolerated medical therapy and laser, though some patients — particularly those with advanced disease at diagnosis — proceed to surgery earlier.

Minimally invasive glaucoma surgery (MIGS) encompasses a growing category of procedures that access the trabecular meshwork, Schlemm's canal, or suprachoroidal space through microincisions, often combined with cataract surgery. MIGS procedures — including iStent inject, Hydrus microstent, gonioscopy-assisted transluminal trabeculotomy (GATT), and Kahook Dual Blade goniotomy — offer modest IOP reduction (typically 20–30%) with excellent safety profiles, making them appropriate for mild to moderate glaucoma.

Trabeculectomy, the traditional gold standard filtering surgery, creates a new outflow pathway (bleb) under the conjunctiva. It achieves greater IOP reduction (often below 12 mmHg) than MIGS but carries higher complication risks including bleb failure, hypotony, cataract formation, and infection (blebitis/endophthalmitis). Glaucoma drainage devices (tube shunts — Baerveldt, Ahmed) route aqueous to a reservoir plate, offering alternatives for eyes with complex anatomy or failed trabeculectomies.

Neuroprotection, Monitoring, and the Future

Beyond IOP reduction, researchers are actively pursuing neuroprotective strategies that could independently protect retinal ganglion cells from apoptosis — the final common pathway of glaucomatous vision loss. Nicotinamide (vitamin B3) showed promising results in a phase 2/3 trial published in 2023, with patients receiving high-dose nicotinamide (1,500–3,000 mg/day) demonstrating slower visual field progression than controls. Larger confirmatory trials are ongoing.

Monitoring glaucoma progression requires regular visual field testing (standard automated perimetry), optic nerve imaging via OCT (optical coherence tomography), and clinical disc examination. The rate of progression — typically expressed as mean deviation change per year on visual field — guides treatment escalation: a patient losing 1 dB/year may have decades of useful vision remaining, while one losing 3 dB/year with already-damaged fields requires urgent intervention.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.